Abstract
Experimental evidences on the adaptive immune response in patients with hereditary hemorragic telagiectasia (HHT) are lacking. Here, we report in 9 patients with HHT a multiple deficit involving the intracellular expression of T helper (h)1-derived cytokines [Interferon (IFN)-γ, Interleukin (IL)-2 and Tumor Necrosis Factor (TNF)-α] and of monocyte- derived TNF-α. On the other hand, percentages of Th2-derived cytokines (IL-4, IL-5 and IL-10) were normal or, in some cases, above normality. Quite interestingly, monocyte-derived IL-10 was detectable in 5 out of 9 patients in a percentage of cells comparable to controls or exceeding normal levels. Taken together, these data point out, in HHT, an ablation of Th1-responses, while Th2-type cytokines are preserved, thus exerting either a suppressive effect on Th1-cells (via IL-4 and IL-10) or an antiinflammatory response on monocyte-derived TNF-α (via IL-10). Furthermore, monocytederived IL-10 may also contribute to the antiinflammatory activity seen in HHT. According to current literature even if patients with HHT do not exhibit certain diseases, such as autoimmune diseases, cancer and abnormal responses to pathogens, the observed immune deficits need to be diagnosed and therapeutically corrected.
Keywords: Cytokines, hereditary hemorrhagic teleangiectasia, monocytes, T-Lymphocytes
Current Pharmaceutical Design
Title: Ablation of T-Helper 1 Cell Derived Cytokines and of Monocyte-Derived Tumor Necrosis Factor-α in Hereditary Hemorrhagic Telangiectasia: Immunological Consequences and Clinical Considerations
Volume: 12 Issue: 10
Author(s): F. Resta, V. Triggiani, E. Jirillo, C. Sabba, L. Amati and M. E. Passeri
Affiliation:
Keywords: Cytokines, hereditary hemorrhagic teleangiectasia, monocytes, T-Lymphocytes
Abstract: Experimental evidences on the adaptive immune response in patients with hereditary hemorragic telagiectasia (HHT) are lacking. Here, we report in 9 patients with HHT a multiple deficit involving the intracellular expression of T helper (h)1-derived cytokines [Interferon (IFN)-γ, Interleukin (IL)-2 and Tumor Necrosis Factor (TNF)-α] and of monocyte- derived TNF-α. On the other hand, percentages of Th2-derived cytokines (IL-4, IL-5 and IL-10) were normal or, in some cases, above normality. Quite interestingly, monocyte-derived IL-10 was detectable in 5 out of 9 patients in a percentage of cells comparable to controls or exceeding normal levels. Taken together, these data point out, in HHT, an ablation of Th1-responses, while Th2-type cytokines are preserved, thus exerting either a suppressive effect on Th1-cells (via IL-4 and IL-10) or an antiinflammatory response on monocyte-derived TNF-α (via IL-10). Furthermore, monocytederived IL-10 may also contribute to the antiinflammatory activity seen in HHT. According to current literature even if patients with HHT do not exhibit certain diseases, such as autoimmune diseases, cancer and abnormal responses to pathogens, the observed immune deficits need to be diagnosed and therapeutically corrected.
Export Options
About this article
Cite this article as:
Resta F., Triggiani V., Jirillo E., Sabba C., Amati L. and Passeri E. M., Ablation of T-Helper 1 Cell Derived Cytokines and of Monocyte-Derived Tumor Necrosis Factor-α in Hereditary Hemorrhagic Telangiectasia: Immunological Consequences and Clinical Considerations, Current Pharmaceutical Design 2006; 12 (10) . https://dx.doi.org/10.2174/138161206776361372
DOI https://dx.doi.org/10.2174/138161206776361372 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitors of AP-1 and NF-κB Mediated Transcriptional Activation: Therapeutic Potential in Autoimmune Diseases and Structural Diversity
Current Medicinal Chemistry Experimental Models of Relapsing-Remitting Multiple Sclerosis: Current Concepts and Perspective
Current Neurovascular Research Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design Recent Advances in Regulatory T Cell Therapy of Autoimmunity, Graft Rejection and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery Evidence that Pregnancy Specific Glycoproteins Regulate T-Cell Function and Inflammatory Autoimmune Disease During Pregnancy
Current Drug Targets - Inflammation & Allergy Biological Therapies of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Modulation of Hepatocyte Apoptosis: Cross-talk Between Bile Acids and Nuclear Steroid Receptors
Current Medicinal Chemistry Metabolic Changes in Autoimmune Diseases
Current Drug Discovery Technologies Low 25 Hydroxyvitamin D Levels are Independently Associated with Autoimmune Thyroiditis in a Cohort of Apparently Healthy Overweight and Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Chlorogenic Acid Suppresses a Cell Adhesion Molecule in Experimental Autoimmune Myocarditis in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Regulatory T Cell Therapy for Type I Diabetes Targeting on β Cell Associated Autoantigens
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) B Cells and Beyond: Therapeutic Opportunities Targeting Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Mesenchymal Stromal Cells in Rheumatoid Arthritis: Biological Properties and Clinical Applications
Current Stem Cell Research & Therapy Recent Patents on the Treatment of Type 1 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Interleukin-7: a key Mediator in T Cell-driven Autoimmunity, Inflammation, and Tissue Destruction
Current Pharmaceutical Design Synthesis and Evaluation of Cytotoxicity and Inhibitory Effect on Nitric Oxide Production by J774A.1 Macrophages of New Anthraquinone Derivatives
Medicinal Chemistry Structure, Function and Biological Relevance of Prolyl Oligopeptidase
Current Protein & Peptide Science Further Vitamin D Analogs
Current Vascular Pharmacology Potassium Channel Blockade by the Sea Anemone Toxin ShK for the Treatment of Multiple Sclerosis and Other Autoimmune Diseases
Current Medicinal Chemistry Computational Studies Applied to Anti-inflammatory Drug Discovery: A Review
Current Organic Chemistry